Outline

- HIV
- Hepatitis C
- HCV/HIV risk factors for transmission
- HCV/HIV – Who’s at risk?
- HCV/HIV – Health outcomes
- MIDAP
- HCV/HIV MIDAP Project
- Next Steps
HIV

- Effective and well-tolerated treatments
- U=U
- Expect to live an essentially normal lifespan
- Need to address co-occurring health conditions
Hepatitis C (HCV)

- One in four people with HIV have been infected with HCV at some point in their life
- HCV is a serious health threat that can cause liver damage, cancer, and even death if left untreated
- No vaccine
- Interferon

HCV was not included in most routine health screenings and universal precautions to prevent transmission in health care settings
HCV/HIV Risk Factors for Transmission

- Sexual transmission of hepatitis C = RARE
- Sexual transmission of HIV = COMMON
- IDU – most likely to have both viruses

HCV/HIV – Who’s at risk?

- Younger
- Male
- African American
- Low-income
- Publicly insured
- Less likely to see a liver specialist or receive hep C treatment
- Increased comorbidities
- Increased liver complications
- Increased mortality
HCV/HIV Health Outcomes

- Health outcomes are worse
- 5-24% spontaneous clearing of HCV infection without medication\textsuperscript{5,6}
- Accelerates liver disease progression\textsuperscript{7}
- Difficulty for person’s liver to properly process HIV antiretrovirals $\rightarrow$ hepatotoxicity and increased risk of death\textsuperscript{8,9,10}
Summary

- Increase testing!!!
- HIV/HCV co-infected patients suffer significantly higher mortality, live-related mortality, liver cancer, and liver decompensation than HCV mono-infected patients.
- Encourage MIDAP clients to seek treatment!
What is the Michigan Drug Assistance Program (MIDAP)?

The Michigan Drug Assistance Program (MIDAP) is a federally funded program that provides HIV-related (and other related medications) to eligible applicants who have limited or no access to insurance coverage.

In order to be eligible for MIDAP, applicants must meet the following criteria:

- Provide proof of HIV Status
- Be a resident of the State of Michigan
- Have a gross income between 138%-500% of the Federal Poverty Level (FPL)
- Not eligible for any other program—MIDAP is the payer of last resort
MIDAP/HCV

- March 1, 2018 – MIDAP added four hepatitis C medications to the MIDAP formulary for eligible individuals co-infected with HIV and hepatitis C.
- Epclusa, Harvoni, Mavyret, and Zepatier
- Eligibility:
  - Living with HIV
  - On MIDAP and uninsured or insurance does not cover needed HCV medication
  - Documentation of diagnosis of hepatitis C
  - PA form similar to Medicaid HCV PA form (provider restrictions & sobriety restrictions, 3 months vs 6 months)

Link to MIDAP HCV/HIV PA Request Form
http://www.scriptguiderx.com/content/forms/MDHHS_MIDAP_Hep_C_Prior_Auth_Form.pdf
MIDAP/HCV Project

- In 2018, MIDAP started to cover four HCV DAAs, only 2 MIDAP/HCV clients were treated for hepatitis C

- Goal for 2019:
  - Identify all MIDAP clients that are coinfected with HCV
  - Identify all MIDAP/HCV clients HIV treatment providers
  - Better understand the reasons why patients have not started HCV treatment
  - Increase the number of 2 treated for HCV on MIDAP to 10 for 2019
Methods

- MIDAP roster
- HCV cases – MDSS
- Link Plus
  - 99 MIDAP clients coinfected with HCV
- 76 Co-infected
- Data to care
  - 1 client NIC
- Client descriptives – CAREWare
- Met with local and state partners
- Identified client’s HIV provider and if HCV treatment status (initiated/completed) – ScriptGuideRX & NPI lookup
MIDAP/HCV Project

Sex

Race

HIV Risk Factors

- Female: 15.8%
- Male: 84.2%

Case No.

- Black: 30
- White: 40
- Asian/Pacific Islander: 5
- American Indian/Alaska Native: 1
- Other: 0

Case No.

- MSM: 53.1%
- IDU: 21.1%
- Heterosexual: 17.1%
- Unk: 17.1%
MIDAP/HCV Project

Income

HCV Genotype

Diagnosis Age (years)

<table>
<thead>
<tr>
<th></th>
<th>Range</th>
<th>Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>19 – 66</td>
<td>38.5</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>17 - 69</td>
<td>52</td>
</tr>
</tbody>
</table>
MIDAP/HCV Project

- Contacted providers via email
  - Provided them with information regarding the MIDAP/HCV project
  - About MIDAP and how MIDAP will cover eligible clients
- MIDAP/HCV PA Form
- Excel Spreadsheet – Patient Panel
Next Steps & Future Goals

- Start hearing back from providers
  - Majority are ID providers who can prescribe HCV DAAs
  - Better understand reasons for why clients had not started HCV treatment
- Educate providers on MIDAP and how eligible clients can be treated
- Increase last years number from 2 to 10
- Explore contacting HIV Case Managers?
- Expanding the project beyond MIDAP clients?
- Better system of identify folks who are coinfected
- MIDAP/HCV project aligns with the Ryan White HIV/AIDS Program role in eliminating HCV among people with HIV in the U.S.
References


9 van de Laar, et. al., supra, at note 5.

Questions?

Macey Ladisky, MPH
Viral Hepatitis Patient Navigator
Viral Hepatitis, HAI, TB and Body Art Licensure Section
Division of Communicable Diseases
MDHHS
Office Phone: 517-284-4958
ladiskym@Michigan.gov

Shelli Doll, MA, CHES
Michigan Drug Assistance Program
HIV Care and Prevention Section
Division of HIV and STD Programs
MDHHS
Office Phone: 517-241-0966
Dolls@Michigan.gov